HomeCompareTCPC vs BDX

TCPC vs BDX: Dividend Comparison 2026

TCPC yields 28.25% · BDX yields 2.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TCPC wins by $22.1K in total portfolio value
10 years
TCPC
TCPC
● Live price
28.25%
Share price
$3.54
Annual div
$1.00
5Y div CAGR
-15.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.0K
Annual income
$1,317.64
Full TCPC calculator →
BDX
BDX
● Live price
2.27%
Share price
$154.69
Annual div
$3.51
5Y div CAGR
13.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.9K
Annual income
$1,058.14
Full BDX calculator →

Portfolio growth — TCPC vs BDX

📍 TCPC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTCPCBDX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TCPC + BDX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TCPC pays
BDX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TCPC
Annual income on $10K today (after 15% tax)
$2,401.13/yr
After 10yr DRIP, annual income (after tax)
$1,119.99/yr
BDX
Annual income on $10K today (after 15% tax)
$192.91/yr
After 10yr DRIP, annual income (after tax)
$899.42/yr
At 15% tax rate, TCPC beats the other by $220.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TCPC + BDX for your $10,000?

TCPC: 50%BDX: 50%
100% BDX50/50100% TCPC
Portfolio after 10yr
$38.0K
Annual income
$1,187.89/yr
Blended yield
3.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BDX right now

TCPC
Analyst Ratings
4
Buy
7
Hold
2
Sell
Consensus: Hold
Price Target
$8.00
+126.0% upside vs current
Range: $8.00 — $8.00
Altman Z
-1.0
Piotroski
6/9
BDX
Analyst Ratings
16
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$193.80
+25.3% upside vs current
Range: $170.00 — $215.00
Altman Z
2.1
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TCPC buys
0
BDX buys
12
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$BDX▲ Buy$1,001 - $15,0002025-09-29
Lisa McClain🏢 House$BDX▼ Sell$1,001 - $15,0002025-06-24
Lisa McClain🏢 House$BDX▲ Buy$1,001 - $15,0002025-06-17
Rob Bresnahan🏢 House$BDX▲ Buy$1,001 - $15,0002025-05-15
Thomas H. Kean🏢 House$BDX▲ Buy$1,001 - $15,0002025-05-13
Rob Bresnahan🏢 House$BDX▼ Sell$1,001 - $15,0002025-04-08
Jefferson Shreve🏢 House$BDX▼ Sell$15,001 - $50,0002025-03-05
William R. Keating🏢 House$BDX▼ Sell$1,001 - $15,0002024-09-11
Ro Khanna🏢 House$BDX▼ Sell$1,001 - $15,0002024-09-09
John James🏢 House$BDX▼ Sell$1,001 - $15,0002024-09-04
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTCPCBDX
Forward yield28.25%2.27%
Annual dividend / share$1.00$3.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-15.2%13.5%
Portfolio after 10y$49.0K$26.9K
Annual income after 10y$1,317.64$1,058.14
Total dividends collected$20.5K$5.7K
Payment frequencyquarterlyquarterly
SectorBDCHealthcare
Analyst consensusHoldBuy
Analyst price target$8.00$193.80

Year-by-year: TCPC vs BDX ($10,000, DRIP)

YearTCPC PortfolioTCPC Income/yrBDX PortfolioBDX Income/yrGap
1← crossover$13,095$2,395.48$10,958$257.59+$2.1KTCPC
2$16,498$2,486.14$12,024$299.40+$4.5KTCPC
3$20,135$2,482.31$13,214$348.50+$6.9KTCPC
4$23,946$2,400.99$14,545$406.26+$9.4KTCPC
5$27,885$2,262.94$16,038$474.35+$11.8KTCPC
6$31,926$2,088.46$17,715$554.80+$14.2KTCPC
7$36,055$1,894.98$19,606$650.06+$16.4KTCPC
8$40,275$1,696.08$21,741$763.12+$18.5KTCPC
9$44,596$1,501.51$24,161$897.64+$20.4KTCPC
10$49,035$1,317.64$26,910$1,058.14+$22.1KTCPC

TCPC vs BDX: Complete Analysis 2026

TCPCBDC

BlackRock TCP Capital Corp. is a business development company specializing in direct equity and debt investments in middle-market, debt securities, senior secured loans, junior loans, originated loans, mezzanine, senior debt instruments, bonds, and secondary-market investments. It typically invests in communication services, public relations services, television, wireless telecommunication services, apparel, textile mills, restaurants, retailing, energy, oil and gas extraction, Patent owners and Lessors, Federal and Federally- Sponsored Credit agencies, insurance, hospital and healthcare centers, Biotechnology, engineering services, heavy electrical equipment, tax accounting, scientific and related consulting services, charter freight air transportation, Information technology consulting, application hosting services, software diagram and design, computer aided design, communication equipment, electronics manufacturing equipment, computer components, chemicals. It seeks to invest in the United States. The fund typically invests between $10 million and $35 million in companies with enterprise values between $100 million and $1500 million including complex situations. It prefers to make equity investments in companies for an ownership stake.

Full TCPC Calculator →

BDXHealthcare

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Full BDX Calculator →
📬

Get this TCPC vs BDX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TCPC vs SCHDTCPC vs JEPITCPC vs OTCPC vs KOTCPC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.